1. Introduction {#sec1-cancers-10-00434}
===============

Lung cancer is a leading cause of death in the world. Platinum-based chemotherapy had been a standard therapy for metastatic lung cancer, but the treatment result is still limited and disappointing. In the past decade, non-small cell lung cancer (NSCLC) patients had been proved to have longer progression-free survival (PFS) and better response rate to epidermal growth factor receptor (*EGFR*) tyrosine kinase inhibitors (TKIs) if they a had sensitizing *EGFR* mutation in phase 3 clinical trials \[[@B1-cancers-10-00434],[@B2-cancers-10-00434],[@B3-cancers-10-00434],[@B4-cancers-10-00434],[@B5-cancers-10-00434]\]. Therefore, *EGFR* TKIs had been the standard therapy in NSCLC patients with *EGFR* mutation. Of all *EGFR* mutations in lung cancer, approximately 90% are common mutations, including in-frame deletions in exon 19 and an L858R point mutation in exon 21 \[[@B5-cancers-10-00434],[@B6-cancers-10-00434],[@B7-cancers-10-00434]\]. However, many uncommon mutations, also called rare or non-classical mutations, were detected but the response to *EGFR* TKIs was inconsistent due to a limited number of cases enrolled in the trials \[[@B8-cancers-10-00434],[@B9-cancers-10-00434],[@B10-cancers-10-00434],[@B11-cancers-10-00434],[@B12-cancers-10-00434],[@B13-cancers-10-00434],[@B14-cancers-10-00434]\]. For example, Chiu et al. claimed that both gefitinib and erlotinib are active in lung adenocarcinoma patients with G719X/L861Q/S768I mutations but they had short PFS (a median of 7.7 months) than in those with common *EGFR* mutations (a median of 11.4 months) (*p* \< 0.01) \[[@B13-cancers-10-00434]\]. A post-hoc analysis of the LUX-Lung 2, 3 and 6 trials demonstrated that patients harboring G719X, L861G, or S768I mutation responded to afatinib \[[@B15-cancers-10-00434]\]. In a retrospective study by Shen et al., afatinib provided significantly better PFS than gefitinib/erlotinib in 51 patients with stage IIIB-IV lung adenocarcinoma with non-classical mutations (median PFS: 11.0 vs. 3.6 months, *p* = 0.03) \[[@B9-cancers-10-00434]\]. Tu et al. indicated that non-classical mutations were more common in smokers (30.7% vs. 24.3%, *p* = 0.039) and males (54.1% vs. 44.4%, *p* = 0.007), and favorable efficacy was observed in patients harboring L858R mutation (median PFS: 15.2 months) or G719X mutation (median PFS: 11.6 months) \[[@B8-cancers-10-00434]\].

Identifying the predicting factors for the clinical efficacy of *EGFR* TKIs in these patients with lung adenocarcinoma harboring uncommon *EGFR* mutation is urgent. We, therefore, conducted a retrospective study in two university-affiliated hospitals. We made a comprehensive analysis of the clinical efficacy of three different *EGFR* TKIs in these patients.

2. Patients and Methods {#sec2-cancers-10-00434}
=======================

2.1. Patient Identification {#sec2dot1-cancers-10-00434}
---------------------------

In this retrospective study, all patients of lung adenocarcinoma diagnosed and received *EGFR* mutation exam in two university-affiliated hospitals in Taiwan between January 2009 and March 2018 were screened. All patients had uncommon *EGFR* mutation and received an *EGFR* TKI were enrolled and followed until March 2018. The diagnosis of lung cancer was confirmed pathologically, according to World Health Organization pathology classification. The tumor staging was designated according to the seventh American Joint Committee on Cancer staging system by a special committee constituted of clinical pulmonologists, medical oncologists, chest surgeons, radiologists, pathologists and radiation oncologists. Patients were included if: (1) they had adequate tumor specimens for *EGFR* mutation examination, (2) the exam revealed an uncommon *EGFR* gene mutation, and (3) they received an *EGFR* TKI treatment with gefitinib, erlotinib, or afatinib. To clearly identify the effects of *EGFR* TKI as the first-line treatment for stage IV lung adenocarcinoma harboring uncommon mutation, patients with stage I-III cancer and those received an *EGFR* TKI after other treatment modalities were excluded from the further analyses.

As in our previous reports \[[@B16-cancers-10-00434],[@B17-cancers-10-00434],[@B18-cancers-10-00434],[@B19-cancers-10-00434],[@B20-cancers-10-00434],[@B21-cancers-10-00434]\], mutations in *EGFR* gene were analyzed using protocol developed and validated by the Division of Molecular Diagnostics, Department of Laboratory Medicine, Kaohsiung Medical University Hospital (KMUH), which utilized amplification refractory mutation specific (ARMS) polymerase chain reaction (PCR) and Scorpion technologies for the detection, and direct sequencing was performed when a negative result was found in ARMS PCR.

Although a few studies have discussed rare *EGFR* mutation ([Table A1](#cancers-10-00434-t0A1){ref-type="table"}), the most appropriate method for classifying rare *EGFR* mutation remained inconclusive because of the rare entity. Therefore, in addition to classifying the mutation patterns by exons, we also classified the mutations by drug sensitivity, including "single sensitizing uncommon mutation" (exon18 G719X and exon21 L861Q), "multiple sensitizing mutations" (exon18 G719X + exon20 S768I, exon18 G719X + exon21 L861Q, and exon21 L858R + exon20 S768I), "a sensitizing mutation and a resistant uncommon mutation" (exon18 G719X + exon18 other and exon21 L858R + exon20 Q812\*), and "other resistant uncommon mutations" (exon 18 other mutation, exon 20 insertion, and exon 20 point mutation).

Baseline clinical characteristics were collected by retrospective chart review, including age at diagnosis, sex, initial Eastern Cooperative Oncology Group (ECOG) performance status, smoking history. Smoking status was categorized as current smoker or never smoker (\<100 lifetime cigarettes).

Based on serial imaging studies, the Initial treatment response was classified as a progressive disease (PD), stable disease (SD), partial response (PR), or complete response (CR), using the RECIST 1.1 criteria. The primary outcome of this study was PFS on an *EGFR* TKI, defined by the duration between the start of an *EGFR* TKI and the onset of progression under the treatment. The secondary outcome was overall survival (OS), defined by the duration between the date of confirmed diagnosis and the date of death. The study protocol was approved by the KMUH Institutional Review Board (KMUHIRB-E(II)-20150162).

2.2. Statistical Analyses {#sec2dot2-cancers-10-00434}
-------------------------

Continuous variables and categorical variables were compared using the Kruskal-Wallis test and Fisher's exact test, respectively. Survival times, including PFS and OS, were estimated using the Kaplan-Meier method, and differences between the groups were compared using the log-rank test. Cox proportional hazards regression analyses were used to identify the effect of different variables on PFS or OS. After univariate analyses, all variables were included to obtain a maximal model of multivariable analysis to assess the independent effect of different variables. We also used a backward variable selection method, keeping only variables with a *p* value less than 0.15, to develop reduced multivariable models. All statistical analyses were performed using the SAS system (version 9.4 for Windows, SAS Institute Inc., Cary, NC, USA). The statistical significance level was set at a two-sided *p* value of \<0.05.

3. Results {#sec3-cancers-10-00434}
==========

3.1. Patients Characteristics {#sec3dot1-cancers-10-00434}
-----------------------------

In 2958 patients with lung adenocarcinoma having their specimens tested for *EGFR* mutation, a total of 67 patients with lung adenocarcinoma harboring uncommon *EGFR* gene mutations, who had received an *EGFR* TKI treatment, were enrolled. Five patients with stage I to III disease ([Table A2](#cancers-10-00434-t0A2){ref-type="table"}) were excluded from further analyses to control the confounding effects from the cancer stage. In the 62 patients with stage IV lung cancer ([Table 1](#cancers-10-00434-t001){ref-type="table"}), 36 (58%) were female and 26 (42%) were male, and the mean age was 65 years. Most of them were never smokers (71%) and had a performance status of ECOG ≤ 1 (71%). All patients had their tumor positive for thyroid transcription factor 1 (TTF-1), except for a patient whose tumor was not tested. The overall disease control rate on an *EGFR* TKI was 73%, and the median PFS on an *EGFR* TKI was 7.5 months ([Table 1](#cancers-10-00434-t001){ref-type="table"}).

In the patients with stage IV diseases, 57 (92%) patients received an *EGFR* TKI as their first-line treatment. In these patients, similarly, 32 (56%) were female and 25 (44%) were male, and the mean age was 66 years. Most of them were never smokers (70%) and had a performance status of ECOG ≤ 1 (68%). To avoid bias from various preceding lines of treatment, only patients receiving an *EGFR* TKI as the first-line treatment were included for further survival analyses.

3.2. Various Outcomes Related to Different EGFR Mutation Patterns {#sec3dot2-cancers-10-00434}
-----------------------------------------------------------------

In the stage IV patients receiving a first-line *EGFR* TKI, 21 (37%), 16 (28%), 13 (23%), and 7 (12%) had mutation in exons 18, 20, 21, and multiple exons, respectively ([Table 1](#cancers-10-00434-t001){ref-type="table"} and [Table 2](#cancers-10-00434-t002){ref-type="table"}). Patients with their tumors harboring mutations in different exons of *EGFR* were similar in age, sex, smoking history, and performance status. The response rate and disease control rate were significantly higher in those having mutations in multiple exons ([Table 2](#cancers-10-00434-t002){ref-type="table"}). However, no significant difference was noted in the PFS or OS between groups ([Table 2](#cancers-10-00434-t002){ref-type="table"}, [Figure 1](#cancers-10-00434-f001){ref-type="fig"}A,B).

While classifying the *EGFR* mutation pattern by drug sensitivity, the patients were reclassified into 27 (47%) "single sensitizing uncommon mutation", 7 (12%) "multiple sensitizing mutations", 5 (9%) "a sensitizing mutation and a resistant uncommon mutation" (all of them were exon 18 G719X with another exon 18 point mutation), and 18 (32%) "other resistant uncommon mutations" ([Table 1](#cancers-10-00434-t001){ref-type="table"} and [Table 3](#cancers-10-00434-t003){ref-type="table"}). Patients with their tumors harboring different *EGFR* mutation patterns showed significantly different treatment responses to *EGFR* TKIs, while those with "multiple sensitizing mutations" had the best response rate to TKIs ([Table 3](#cancers-10-00434-t003){ref-type="table"}). However, no significant difference was noted in the PFS or OS between groups ([Table 3](#cancers-10-00434-t003){ref-type="table"}, [Figure 1](#cancers-10-00434-f001){ref-type="fig"}C,D).

3.3. Different TKIs Showed Similar Treatment Response {#sec3dot3-cancers-10-00434}
-----------------------------------------------------

In the 57 patients with stage IV disease receiving an *EGFR* TKI as their first-line treatment, 17 (30%), 31 (54%), and 9 (16%) patients used afatinib, gefitinib, and erlotinib, respectively ([Table 4](#cancers-10-00434-t004){ref-type="table"}). The response rate to the TKI was similar in three groups, while patients receiving erlotinib seemed to have a trend for better disease control rate (*p* = 0.0914). No significant difference was noted in the PFS or OS between patients receiving different first-line *EGFR* TKIs ([Table 4](#cancers-10-00434-t004){ref-type="table"}, [Figure 1](#cancers-10-00434-f001){ref-type="fig"}E,F).

3.4. Elder Patients Had Better PFS but Similar OS {#sec3dot4-cancers-10-00434}
-------------------------------------------------

In the patients with stage IV disease receiving first-line *EGFR* TKI, 26 (46%) were elder (age ≥ 65 years old) patients ([Table 5](#cancers-10-00434-t005){ref-type="table"}). There were significantly more male patients in the elder group than in the younger group (62% vs. 29%, *p* = 0.0176). The elder patients had significantly poorer performance status than the younger patients (percentage of patients with EGOG 2-4: 46% vs. 19%, *p* = 0.0453). The response rate to TKI and disease control rate with TKI was similar between the elder and younger patients. The elder patients had a significantly longer PFS than the younger patients (median PFS: 10.5 vs. 5.5 months, *p* = 0.0320), whereas the OS was similar between groups (*p* = 0.8979) ([Table 5](#cancers-10-00434-t005){ref-type="table"}, [Figure 1](#cancers-10-00434-f001){ref-type="fig"}G,H).

3.5. Factors Related to PFS and OS {#sec3dot5-cancers-10-00434}
----------------------------------

Cox regression analyses were used to identify prognostic factors related to the PFS and OS in patients with stage IV lung adenocarcinoma harboring uncommon mutation treated with a first-line *EGFR* TKI. Univariate analyses identified significantly good prognostic factors for PFS included elder age (HR = 0.52 \[95% CI: 0.28--0.95\], *p* = 0.0349) and having a sensitizing mutation and a resistant uncommon mutation (HR = 0.19 \[95% CI: 0.04--0.85\], *p* = 0.0296) ([Table 6](#cancers-10-00434-t006){ref-type="table"}). As for the metastatic site, leptomeningeal metastasis was the only one associated with a trend for poorer PFS ([Table A3](#cancers-10-00434-t0A3){ref-type="table"}). On multivariable analyses, including maximal models and reduced models developed with backward variable selection method, elder age and female sex were independent prognostic factors for better PFS, while the mutation patterns also had significant effects on PFS. Smoking history, performance status, or the types of *EGFR* TKIs did not significantly affect the PFS.

Female sex and never smoker were significant factors for better OS on univariate analyses but became insignificant in the multivariable models ([Table 7](#cancers-10-00434-t007){ref-type="table"}). As for metastatic site, brain and leptomeningeal metastases were associated with poorer OS ([Table A3](#cancers-10-00434-t0A3){ref-type="table"}), while this finding might be biased by small sample size. Better initial performance status remained a significant factor for better OS in the univariate model and multivariable models, including maximal models and the reduced model. The mutation patterns or the types of *EGFR* TKIs did not significantly affect the OS. Elder age was not associated with a better OS on univariate analysis, whereas multivariable models showed that elder age had a trend for better OS.

4. Discussion {#sec4-cancers-10-00434}
=============

In the past decade, *EGFR* TKIs had replaced platinum-based chemotherapy to be a standard therapy in patients of NSCLCs harboring *EGFR* mutation, because many phase 3 randomized controlled trials demonstrated that patients receiving *EGFR* TKIs had better response rate and longer PFS. However, most of these studies enrolled common mutations, including exon 19 deletion mutation and exon 21 L858R point mutation. To date, the effect of *EGFR* TKIs in NSCLCs with uncommon mutations are not completely understood. This study is probably one of the largest-scale comprehensive studies about the effect of a first-line *EGFR* TKI in patients having lung adenocarcinoma harboring uncommon *EGFR* mutations. We found that the elder patients, although having significantly poorer initial performance status, had a significantly longer PFS than the younger patients.

Approximately 90% *EGFR* mutations are exon 19 deletion or exon 21 L858R point mutation, and both of them are sensitizing to *EGFR* TKIs. However, uncommon mutations, also known as non-classic or rare mutations, have been rarely discussed, because they are rarely seen and only parts of them receive first- or second-generation *EGFR* TKIs. Uncommon or non-classical mutation is a heterogeneous group of molecular alterations with variable responses to *EGFR*-targeted drugs. Only several retrospective small-scale studies to date tried to identify the clinical efficacy in these patients but the results were inconclusive \[[@B8-cancers-10-00434],[@B9-cancers-10-00434],[@B10-cancers-10-00434],[@B13-cancers-10-00434],[@B14-cancers-10-00434],[@B22-cancers-10-00434],[@B23-cancers-10-00434],[@B24-cancers-10-00434]\]. Exon 18 G719X, exon 20 S768I, and exon 21 L861Q are generally considered as sensitizing uncommon mutations. In contrast, the de novo exon 20 T790M mutation and exon 20 insertion predict primary resistance to clinically achievable levels of *EGFR* TKIs \[[@B8-cancers-10-00434],[@B9-cancers-10-00434],[@B14-cancers-10-00434]\].

Patients with lung cancer harboring a "single sensitizing uncommon mutation", including G719X, S768I, and L861Q, usually had a good treatment response to EGFR TKI, although the response was generally still inferior to those harboring common sensitizing mutations. Chen et al. reported that the patients with NSCLC harboring a single uncommon sensitizing mutation (either G719X, L861Q, or S768I) had a response rate of 32.4% and disease control rate of 83.8% \[[@B14-cancers-10-00434]\]. Yun et al. showed G719S mutation had a 14-fold higher affinity to adenosine triphosphate than the wild-type but a weaker affinity to gefitinib than L858R mutation, suggesting that gefitinib could inhibit cancers harboring G719S mutation with less effectiveness \[[@B6-cancers-10-00434]\]. Both studies by Chen et al. \[[@B7-cancers-10-00434]\] and Kancha et al. \[[@B25-cancers-10-00434]\] indicated S768I mutation had resistance to *EGFR* TKI in vitro, but some case reports indicated S768I mutation was still responsive to *EGFR* TKI clinically. In our current study, the patients with adenocarcinoma harboring a single sensitizing uncommon mutation had a fine initial treatment response to first-line *EGFR* TKIs (disease control rate of 85%), PFS (median, 7.7 months), and OS (median, 18.4 months).

Some uncommon mutations are sporadic, and most of them are resistant to an *EGFR* TKI. Shen et al. showed that G779F, L747P, and M825L with R831C were sensitizing mutations, whereas V717G, I715V, K716E, and complex non-classic mutation, such as V742F, A743V, and H773R, were resistant mutations \[[@B9-cancers-10-00434]\]. Ibrahim et al. reported a patient with stage IV lung adenocarcinoma harboring delE709 T710insD in exon 18 who had a good response to afatinib \[[@B26-cancers-10-00434]\].

In patients with lung cancer harboring uncommon mutation, a few of them had compound mutations. "Multiple sensitizing mutations" is a complex group, mostly having co-existing sensitizing mutations in different exons. Chiu et al. reported that co-existence of G719X and L861Q had a high objective response rate of 88.9% but co-existence of G719X and S768I had an objective response rate of only 50%. They further indicated that patients with compound uncommon *EGFR* mutations (G719X + L861Q or G719X + S768I) had a significantly longer PFS than the patients with a single mutation did (median PFS: 11.9 vs. 6.5 months; *p* = 0.010) \[[@B13-cancers-10-00434]\]. In a report by Kobayashi et al., two cases with tumor harboring G719X + S768I had partial responses to erlotinib but the PFSs were only 5 and 7 months \[[@B11-cancers-10-00434]\]. Tu et al. reported that patients with lung cancer harboring compound L858R mutations and G719X mutations, which comprised the majority of uncommon *EGFR* mutations, had objective response rates of 75% and 50% and median PFSs of 15.2 and 11.6 months, respectively \[[@B8-cancers-10-00434]\]. However, Chen et al. presented several cases with cancer harboring G719X + L861Q or G719X + S768I, who had no response to *EGFR* TKI \[[@B14-cancers-10-00434]\]. Our present study indicated that the "multiple sensitizing mutations" group had a significantly better initial treatment response to first-line *EGFR* TKI (response rate of 71% and disease control rate of 86%), and a fine PFS (median, 13.5 months), and OS (median, 20.5 months). Nevertheless, these cases were very rare and heterogeneous, and a simple conclusion is hard to be made.

As another type of compound mutation, an even smaller group of patients had their cancer harboring "a sensitizing (common or uncommon) mutation and a resistant uncommon mutation." In the study by Peng et al., five patients had adenocarcinoma harboring L858R compound mutations, including one case of L858R + S768I. The four cases with L858R and a resistant uncommon mutation had a stable disease as the initial treatment response to gefitinib treatment and had a median PFS of 10 months \[[@B10-cancers-10-00434]\]. In the report by Kobayashi et al., a case with adenocarcinoma harboring G719X and a resistant uncommon mutation and two cases with adenocarcinoma harboring L858R and a resistant uncommon mutation had a partial response as the initial treatment response to first-line erlotinib treatment \[[@B11-cancers-10-00434]\]. In another report, a patient with co-existence of I706T and G719A had a good response and a PFS of at least 22 months, but a patient with co-existence of E709K and G719A had a very poor response to *EGFR* TKI \[[@B27-cancers-10-00434]\]. Kauffmann-Guerrero et al. reported a patient with co-existence of G857E and R836R in exon 21, who had a very poor response to *EGFR* TKI \[[@B12-cancers-10-00434]\]. In our current study, interestingly, all of five patients with stage IV adenocarcinoma harboring a sensitizing mutation and a resistant uncommon mutation involved two point mutations in a single exon (exon 18 G719X with another exon 18 point mutation). These patients, treated with a first-line *EGFR* TKI, had a fine initial treatment response rate (40%), disease control rate (80%) and a very long PFS (median PFS: 72.5 months).

Patients with lung cancer harboring a "single sensitizing uncommon mutation", including G719X, S768I, and L861Q, usually had a good treatment response to EGFR TKI, although the response was generally still inferior to those harboring common sensitizing mutations as the report of Chiu et al. \[[@B13-cancers-10-00434]\].

Traditionally, *EGFR* TKIs are less effective to uncommon mutations than to common sensitizing mutations. Some studies indicated that the irreversible *EGFR* TKI such as afatinib might be more effective for the patients with lung cancer harboring an uncommon mutation \[[@B9-cancers-10-00434],[@B15-cancers-10-00434]\]. Yang et al. summarized Lux-Lung series and indicated afatinib was active in NSCLC harboring certain types of uncommon *EGFR* mutations, especially G719X, S768I, and L861Q but was less active in those harboring other uncommon mutation types \[[@B15-cancers-10-00434]\]. In the study by Shen et al., the analysis of 51 patients having lung adenocarcinoma harboring uncommon *EGFR* mutations except for exon 20 insertion showed that afatinib provided significantly longer PFS than gefitinib/erlotinib did (median PFS: 11.0 vs. 3.6 months, *p* = 0.03) \[[@B9-cancers-10-00434]\]. However, the inclusion of patients with stage IIIB disease and those receiving an *EGFR* TKI as the second or third line of treatment, as well as the exclusion of five cases with exon 20 insertion, might confound the analysis. Our current study clearly focused on a clear group with patients receiving an *EGFR* TKI as the first-line treatment for their stage IV lung adenocarcinoma harboring uncommon mutations and found no significant difference in the initial treatment response, PFS, and OS between patients receiving different *EGFR* TKIs.

Several studies have tried to demonstrate the prognostic factors of lung cancer patients. In a study of patients receiving *EGFR* TKI (as any line of treatment) for advanced lung adenocarcinoma harboring (either common or uncommon) *EGFR* mutation by Chiu et al. \[[@B13-cancers-10-00434]\], female sex, elderly (age \> 70 years), and common *EGFR* mutation were independent factors suggesting better PFS. However, the analysis might be confounded by the enrollment of patients with stage IIIB disease and those receiving *EGFR* TKI as the second- or later-line treatment and by the absence of patients receiving afatinib. In addition, these studies did not report the prognostic factors specifically in the uncommon mutation group. In the current study, we first identified that the elder was an independent prognostic factor for better PFS in the patients treated with a first-line *EGFR* TKI for their stage IV lung adenocarcinoma harboring uncommon mutation.

Furthermore, large-scale prospective studies are warranted to elucidate the efficacy and prognostic factors of different EGFR TKIs in patients with different rare or compound mutations. Osimertinib, a 3rd generation EGFR TKI, has been used to treat the de novo T790M mutation \[[@B28-cancers-10-00434]\], and several case reports have demonstrated that it may be effective in some patients harboring uncommon mutations \[[@B29-cancers-10-00434],[@B30-cancers-10-00434]\]. However, more evidence is still needed.

Several limitations of this study should be addressed. First of all, this study was retrospective, and selection bias cannot be completely avoided. Many patients with uncommon mutation did not receive *EGFR* TKI because previous studies had shown poor clinical efficacy of *EGFR* TKIs in this group of patients. Second, some patients may not have undergone follow-up imaging on schedule. Although regular imaging follow-up is required for the patients to receive reimbursements for *EGFR* TKIs every three months, missing a follow-up exam still occurs. This and the unavoidable bias from a retrospective study design may be overcome through future well-designed prospective studies. Third, due to the uncommon entity, we might be unable to collect sufficient cases to do the analysis. However, this study might be one of the largest-scale comprehensive studies about this topic to date.

5. Conclusions {#sec5-cancers-10-00434}
==============

In conclusion, the elder patients with stage IV lung adenocarcinoma harboring uncommon *EGFR* mutation, although having significantly poor performance status, may have a longer PFS than the younger patients, while treated with a first-line *EGFR* TKI, but the OS was similar in the elder and younger patients. No significant difference in PFS or OS was observed in patients receiving either gefitinib, erlotinib, or afatinib as the first-line treatment. A further large-scale study is necessary to validate our findings, as well as to determine the best treatment modality for patients with lung adenocarcinoma harboring uncommon *EGFR* mutation.
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cancers-10-00434-t0A1_Table A1

###### 

Studies about lung cancer harboring rare EGFR mutations.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, Year                                                                                N ^†^   EGFR TKIs                                  Categories of Mutation Types                                                                                                                       Response Rate (%)   Median PFS (months)   Median OS (months)
  ------------------------------------------------------------------------------------------- ------- ------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- --------------------- --------------------
  Kobayasi, et al., 2013                                                                      8       Erlotinib                                  Compound mutations (sensitive mutation with other mutation):                                                                                                                                 

  G719X with others (n = 3)                                                                   100%                                                                                                                                                                                                                                            

  L858R with others (n = 3)                                                                   66.7%                                                                                                                                                                                                                                           

  L861Q + E709A (n = 1)                                                                       100%                                                                                                                                                                                                                                            

  delL747_T751+R776S (n = 1)                                                                  100%                                                                                                                                                                                                                                            

  Chiu, et al., 2015                                                                          151     Erlotinib, Gefitinib                       Uncommon mutation\                                                                                                                                 41.6%               7.7                   24.0
                                                                                                                                                 (G719X, L861Q, S768I, G719X + L861Q, and G719X + S768I)                                                                                                                                      

  Common mutation                                                                             66.5%   11.4                                       29.7                                                                                                                                                                                         

  Peng, et al., 2015                                                                          6       Gefitinib                                  L858R compound mutations                                                                                                                           16.7%               12.2                  28.6

  Yang, et al., 2015                                                                          75      Afatinib                                   Group 1: point mutations and duplications in exons 18-21(L861G, G719X, S768I, and other point mutations alone or in combination with each other)   71.1%               10.7                  19.4

  Group 2: de-novo T790M mutation in exon 20 (alone or in combination with other mutations)   14.3%   2.9                                        14.9                                                                                                                                                                                         

  Group 3: exon 20 insertions                                                                 8.7%    2.7                                        9.2                                                                                                                                                                                          

  Chen, et al., 2017                                                                          66      Icotinib, Gefitinib, Erlotinib, Afatinib   Group 1: sensitizing rare mutations (G719X, L861Q, S768I)                                                                                          32.4%               4.1                   

  Group 2: resistant mutation (exon 20 insertion)                                             11.1%   3.1                                                                                                                                                                                                                                     

  Group 3: complex mutation (L858R + T790M)                                                   30%     8.6                                                                                                                                                                                                                                     

  Kauffmann-Guerrero, et al., 2017                                                            12      Erlotinib, Afatinib                        Rare mutation                                                                                                                                      28.5                                      

  Complex mutation                                                                            20%                                                                                                                                                                                                                                             

  Tu, et al., 2018                                                                            62      EGFR TKIs                                  G719X                                                                                                                                              50%                 11.6                  25.2

  Exon 20 insertion                                                                           0%      3                                          12.5                                                                                                                                                                                         

  T790M                                                                                       0%      1                                          2.4                                                                                                                                                                                          

  Complex L858R                                                                               75%     15.2                                       27.7                                                                                                                                                                                         

  Others                                                                                      10%     2.9                                        11.7                                                                                                                                                                                         

  Shen, et al., 2018                                                                          56      Gefitinib, Erlotinib, Afatinib             Group 1: exon 20 insertions (except A763_Y764 insFQEA)                                                                                             20%                                       

  Group 2: non-classical mutations with Del19 or L858R                                        58.8%                                                                                                                                                                                                                                           

  Group 3: non-classical mutations without a combination of Del19 or L858R                    58.8%                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor; PR = partial response. ^†^ Case number of the patients receiving an *EGFR* TKI.

cancers-10-00434-t0A2_Table A2

###### 

Patients with stage I to III lung cancer harboring rare EGFR mutation.

  Patient No.   Age   Sex      Smoking        Initial Stage   TTF-1   EGFR Mutation   TKI Treatment                          
  ------------- ----- -------- -------------- --------------- ------- --------------- --------------- ----------- ---------- ----
  1             68    Female   never          IA              \+      exon 21         L861Q           Gefitinib   1st line   PR
  2             60    Female   never          IA              \+      exon 21         L861Q           Afatinib    1st line   SD
  3             42    Male     20 pack-year   IIA             \+      exon 18         G719X           Afatinib    1st line   PD
  4             72    Male     never          IIIA            \+      exon 20         S768I           Erlotinib   2nd line   SD
  5             53    Female   never          IIIB            \+      exon 18         G724S           Gefitinib   2nd line   PR

Abbreviation: ECOG = Eastern Cooperative Oncology Group; TTF-1 = thyroid transcription factor 1, TTF-1 was often used to confirmed the diagnosis of lung adenocarcinoma.

cancers-10-00434-t0A3_Table A3

###### 

Univariate Cox proportional hazards regression analysis to identify the relationship between metastatic sites and survival in patients with stage IV lung cancer harboring rare mutations receiving first-line TKIs.

  Metastatic Site   Progression-Free Survival   Overall Survival                           
  ----------------- --------------------------- ------------------ ----------------------- --------
  Brain             1.68 \[0.77--3.67\]         0.1902             3.82 \[1.57--9.26\]     0.0030
  Leptomeningeal    4.23 \[0.97--18.38\]        0.0545             15.09 \[3.02--75.30\]   0.0009
  Lung              1.03 \[0.56--1.9\]          0.9202             0.63 \[0.31--1.30\]     0.2145
  Bone              1.78 \[0.97--3.29\]         0.0638             1.29 \[0.67--2.47\]     0.4440
  Pleural           1.35 \[0.75--2.44\]         0.3112             1.26 \[0.66--2.39\]     0.4816
  Pericardial       0.94 \[0.33--2.64\]         0.9021             1.01 \[0.31--3.30\]     0.9931
  Liver             1.73 \[0.75--3.97\]         0.1956             1.53 \[0.58--4.04\]     0.3885
  Adrenal           0.5 \[0.15--1.66\]          0.2565             0.36 \[0.08--1.51\]     0.1621

Abbreviation: HR = hazard ratio; CI = confidence interval.

![Kaplan-Meier curves of the progression-free survival (PFS) (**A**,**C**,**E**,**G**) and overall survival (OS) (**B**,**D**,**F**,**H**) of the patients receiving a first-line EGFR TKI, while classified the patients by (**A**,**B**) the exon of EGFR mutation, (**C**,**D**) the drug sensitivity of EGFR mutation, (**E**,**F**) the EGFR TKI used, and (**G**,**H**) the age group. Abbreviation: PFS = progression-free survival; OS = overall survival.](cancers-10-00434-g001){#cancers-10-00434-f001}
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###### 

Characteristics of the patients with stage IV lung cancer harboring uncommon mutation.

                                                              All Stage IV Patients   Patients Receiving First-Line TKI
  ----------------------------------------------------------- ----------------------- -----------------------------------
  n                                                           62                      57
  Age (year), mean ± SD                                       65 ± 12                 66 ± 12
  Age (year), median (IQR)                                    64 (56--74)             65 (56--75)
  Sex, n (%)                                                                          
   Female                                                     36 (58%)                32 (56%)
   Male                                                       26 (42%)                25 (44%)
  Smoking history, n (%)                                                              
   Never                                                      44 (71%)                40 (70%)
   Current                                                    18 (29%)                17 (30%)
  Performance status, n (%)                                                           
   ECOG 0--1                                                  44 (71%)                39 (68%)
   ECOG 2--4                                                  18 (29%)                18 (32%)
  TKI medication, n (%)                                                               
   Afatinib                                                   19 (31%)                17 (30%)
   Gefitinib                                                  32 (52%)                31 (54%)
   Erlotinib                                                  11 (18%)                9 (16%)
  TKI use, n (%)                                                                      
   1st-line treatment                                         57 (92%)                57 (100%)
   2nd-line treatment                                         3 (5%)                  
   after 2nd-line treatment                                   2 (3%)                  
  Number of metastatic sites, n (%)                                                   
   =1                                                         29 (47%)                27 (47%)
   ≥2                                                         33 (53%)                30 (53%)
  Metastatic site, n (%)                                                              
   Brain                                                      16 (26%)                14 (25%)
   Leptomeningeal                                             2 (3%)                  2 (4%)
   Lung                                                       23 (37%)                20 (35%)
   Bone                                                       32 (52%)                30 (53%)
   Pleural                                                    29 (47%)                29 (51%)
   Pericardial                                                5 (8%)                  5 (9%)
   Liver                                                      10 (16%)                9 (16%)
   Adrenal                                                    5 (8%)                  5 (9%)
   Renal                                                      1 (2%)                  0 (0%)
  Mutation site, n (%)                                                                
   Exon 18 G719X                                              14 (23%)                14 (25%)
   Exon 18 other mutation                                     2 (3%)                  2 (4%)
   Exon 18 G719X + exon 18 other mutation                     5 (8%)                  5 (9%)
   Exon 20 insertion                                          16 (26%)                13 (23%)
   Exon 20 point mutation                                     3 (5%)                  3 (5%)
   Exon 21 L861Q                                              13 (21%)                13 (23%)
   Exon 18 G719X + exon 20 S768I                              3 (5%)                  3 (5%)
   Exon 18 G719X + exon 21 L861Q                              2 (3%)                  2 (4%)
   Exon 21 L858R + exon 20 S768I                              3 (5%)                  2 (4%)
   Exon 21 L858R + exon 20 Q812\*                             1 (2%)                  0 (0%)
  Mutation site classified by exon, n (%)                                             
   Mutation only in exon 18                                   21 (34%)                21 (37%)
   Mutation only in exon 20                                   19 (31%)                16 (28%)
   Mutation only in exon 21                                   13 (21%)                13 (23%)
   Mutations in multiple exons                                9 (15%)                 7 (12%)
  Mutation site classified by susceptibility ^†^, n (%)                               
   Single sensitizing uncommon mutation                       27 (44%)                27 (47%)
   Multiple sensitizing mutations                             8 (13%)                 7 (12%)
   A sensitizing mutation and a resistant uncommon mutation   6 (10%)                 5 (9%)
   Other resistant uncommon mutations                         21 (34%)                18 (32%)
  Initial response to TKI, n (%)                                                      
   Partial response                                           21 (34%)                19 (33%)
   Stable disease                                             24 (39%)                22 (39%)
   Progressive disease                                        17 (27%)                16 (28%)
  Response rate to TKI                                        21 (34%)                19 (33%)
  Disease control rate to TKI                                 45 (73%)                41 (72%)
  Median follow-up time (months)                              13.0                    11.5
  Median PFS on TKI (months)                                  7.5                     7.4
  Median OS (month)                                           17.0                    16.1

Abbreviations: ECOG = Eastern Cooperative Oncology Group; TTF-1 = thyroid transcription factor 1. ^†^ Mutation site classified by susceptibility: "Single sensitizing uncommon mutation" included exon18 G719X and exon21 L861Q; "multiple sensitizing mutations" included exon18 G719X + exon20 S768I, exon18 G719X + exon21 L861Q, and exon21 L858R + exon20 S768I; "a sensitizing mutation and a resistant uncommon mutation" included exon18 G719X + exon18 other and exon21 L858R + exon20 Q812\*; "other resistant uncommon mutations" included exon 18 other mutation, exon 20 insertion, and exon 20 point mutation.
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###### 

Characteristics of the patients with stage IV lung cancer harboring uncommon mutation receiving a first-line tyrosine kinase inhibitor (TKI), classified by the exon of epidermal growth factor receptor (*EGFR*) mutation.

                                   Mutation Only in exon 18   Mutation Only in exon 20   Mutation Only in exon 21   Mutations in Multiple Exons   *p* Value \*
  -------------------------------- -------------------------- -------------------------- -------------------------- ----------------------------- --------------
  n                                21 (37%)                   16 (28%)                   13 (23%)                   7 (12%)                       
  Age (year), mean ± SD            66 ± 13                    63 ± 10                    69 ± 13                    64 ± 11                       0.6964
  Age (year), median (IQR)         64 (55--79)                65 (55--70)                67 (56--78)                63 (60--73)                   0.6964
  Age (year), n (%)                                                                                                                               0.7749
   \<65                            11 (52%)                   9 (56%)                    6 (46%)                    5 (71%)                       
   ≥65                             10 (48%)                   7 (44%)                    7 (54%)                    2 (29%)                       
  Sex, n (%)                                                                                                                                      1.0000
   Female                          12 (57%)                   9 (56%)                    7 (54%)                    4 (57%)                       
   Male                            9 (43%)                    7 (44%)                    6 (46%)                    3 (43%)                       
  Smoking history, n (%)                                                                                                                          0.3188
   Never                           14 (67%)                   11 (69%)                   8 (62%)                    7 (100%)                      
   Current                         7 (33%)                    5 (31%)                    5 (38%)                    0 (0%)                        
  Performance status, n (%)                                                                                                                       0.0799
   ECOG 0--1                       17 (81%)                   7 (44%)                    9 (69%)                    6 (86%)                       
   ECOG 2--4                       4 (19%)                    9 (56%)                    4 (31%)                    1 (14%)                       
  No. of metastatic sites, n (%)                                                                                                                  0.3715
   =1                              11 (52%)                   7 (44%)                    4 (31%)                    5 (71%)                       
   ≥2                              10 (48%)                   9 (56%)                    9 (69%)                    2 (29%)                       
  Metastatic site, n (%)                                                                                                                          
   Brain                           5 (24%)                    5 (31%)                    3 (23%)                    1 (14%)                       0.8976
   Leptomeningeal                  0 (0%)                     2 (13%)                    0 (0%)                     0 (0%)                        0.2644
   Lung                            4 (19%)                    5 (31%)                    9 (69%)                    2 (29%)                       0.0288
   Bone                            11 (52%)                   8 (50%)                    9 (69%)                    2 (29%)                       0.3946
   Pleural                         11 (52%)                   8 (50%)                    7 (54%)                    3 (43%)                       1.0000
   Pericardial                     3 (14%)                    0 (0%)                     1 (8%)                     1 (14%)                       0.4222
   Liver                           1 (5%)                     2 (13%)                    6 (46%)                    0 (0%)                        0.0109
   Adrenal                         3 (14%)                    2 (13%)                    0 (0%)                     0 (0%)                        0.5324
  TKI medication, n (%)                                                                                                                           0.2374
   Afatinib                        4 (19%)                    8 (50%)                    2 (15%)                    3 (43%)                       
   Gefitinib                       14 (67%)                   7 (44%)                    7 (54%)                    3 (43%)                       
   Erlotinib                       3 (14%)                    1 (6%)                     4 (31%)                    1 (14%)                       
  Initial response to TKI, n (%)                                                                                                                  0.0212
  Partial response                 8 (38%)                    1 (6%)                     5 (38%)                    5 (71%)                       
  Stable disease                   10 (48%)                   6 (38%)                    5 (38%)                    1 (14%)                       
  Progressive disease              3 (14%)                    9 (56%)                    3 (23%)                    1 (14%)                       
  Response rate to TKI             8 (38%)                    1 (6%)                     5 (38%)                    5 (71%)                       0.0118
  Disease control rate with TKI    18 (86%)                   7 (44%)                    10 (77%)                   6 (86%)                       0.0357
  Median PFS on TKI (month)        9.2                        2.8                        9.0                        13.5                          0.1592
  Median OS (month)                20.0                       14.7                       17.0                       20.5                          0.6596

\* Kruskal-Wallis test or Fisher's exact test or Log-rank test.
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###### 

Characteristics of the patients with stage IV lung cancer harboring uncommon mutation receiving a first-line tyrosine kinase inhibitor (TKI), classified by the drug susceptibility of EGFR mutation ^†^.

                                      Single Sensitizing Uncommon Mutation   Multiple Sensitizing Uncommon Mutations   A Sensitizing Mutation and a Resistant Uncommon Mutation   Other Resistant Uncommon Mutations   *p* Value \*
  ----------------------------------- -------------------------------------- ----------------------------------------- ---------------------------------------------------------- ------------------------------------ --------------
  n                                   27 (47%)                               7 (12%)                                   5 (9%)                                                     18 (32%)                             
  Age (year), mean ± SD               67 ± 12                                64 ± 11                                   77 ± 13                                                    61 ± 10                              0.0971
  Age (year), median (IQR)            64 (56--78)                            63 (60--73)                               84 (75--85)                                                64 (49--70)                          0.0971
  Age (year), n (%)                                                                                                                                                                                                    0.3426
   \<65                               14 (52%)                               5 (71%)                                   1 (20%)                                                    11 (61%)                             
   ≥65                                13 (48%)                               2 (29%)                                   4 (80%)                                                    7 (39%)                              
  Sex, n (%)                                                                                                                                                                                                           0.4195
   Female                             17 (63%)                               4 (57%)                                   1 (20%)                                                    10 (56%)                             
   Male                               10 (37%)                               3 (43%)                                   4 (80%)                                                    8 (44%)                              
  Smoking history, n (%)                                                                                                                                                                                               0.0286
   Never                              20 (74%)                               7 (100%)                                  1 (20%)                                                    12 (67%)                             
   Current                            7 (26%)                                0 (0%)                                    4 (80%)                                                    6 (33%)                              
  Performance status, n (%)                                                                                                                                                                                            0.1784
   ECOG 0-1                           21 (78%)                               6 (86%)                                   3 (60%)                                                    9 (50%)                              
   ECOG 2-4                           6 (22%)                                1 (14%)                                   2 (40%)                                                    9 (50%)                              
  Number of metastatic sites, n (%)                                                                                                                                                                                    0.1168
   =1                                 9 (33%)                                5 (71%)                                   4 (80%)                                                    9 (50%)                              
   ≥2                                 18 (67%)                               2 (29%)                                   1 (20%)                                                    9 (50%)                              
  Metastatic site, n (%)                                                                                                                                                                                               
   Brain                              7 (26%)                                1 (14%)                                   1 (20%)                                                    5 (28%)                              0.9629
   Leptomeningeal                     0 (0%)                                 0 (0%)                                    0 (0%)                                                     2 (11%)                              0.3571
   Lung                               13 (48%)                               2 (29%)                                   0 (0%)                                                     5 (28%)                              0.1805
   Bone                               18 (67%)                               2 (29%)                                   1 (20%)                                                    9 (50%)                              0.1168
   Pleural                            15 (56%)                               3 (43%)                                   3 (60%)                                                    8 (44%)                              0.8305
   Pericardial                        3 (11%)                                1 (14%)                                   0 (0%)                                                     1 (6%)                               0.8033
   Liver                              7 (26%)                                0 (0%)                                    0 (0%)                                                     2 (11%)                              0.3156
   Adrenal                            2 (7%)                                 0 (0%)                                    1 (20%)                                                    2 (11%)                              0.5715
  TKI medication, n (%)                                                                                                                                                                                                0.1599
   Afatinib                           5 (19%)                                3 (43%)                                   0 (0%)                                                     9 (50%)                              
   Gefitinib                          16 (59%)                               3 (43%)                                   4 (80%)                                                    8 (44%)                              
   Erlotinib                          6 (22%)                                1 (14%)                                   1 (20%)                                                    1 (6%)                               
  Initial response to TKI, n (%)                                                                                                                                                                                       0.0062
   Partial response                   11 (41%)                               5 (71%)                                   2 (40%)                                                    1 (6%)                               
   Stable disease                     12 (44%)                               1 (14%)                                   2 (40%)                                                    7 (39%)                              
   Progressive disease                4 (15%)                                1 (14%)                                   1 (20%)                                                    10 (56%)                             
  Response rate to TKI                11 (41%)                               5 (71%)                                   2 (40%)                                                    1 (6%)                               0.0037
  Disease control rate with TKI       23 (85%)                               6 (86%)                                   4 (80%)                                                    8 (44%)                              0.0188
  Median PFS on TKI (month)           7.7                                    13.5                                      72.5                                                       3.1                                  0.0583
  Median OS (month)                   18.4                                   20.5                                      11.0                                                       14.7                                 0.7754

\* Kruskal-Wallis test or Fisher's exact test or Log-rank test. ^†^ Mutation site classified by susceptibility: "Single sensitizing uncommon mutation" included exon18 G719X and exon21 L861Q; "multiple sensitizing mutations" included exon18 G719X + exon20 S768I, exon18 G719X + exon21 L861Q, and exon21 L858R + exon20 S768I; "a sensitizing mutation and a resistant uncommon mutation" included exon18 G719X + exon18 other and exon21 L858R + exon20 Q812\*; "other resistant uncommon mutations" included exon 18 other mutation, exon 20 insertion, and exon 20 point mutation.
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###### 

Characteristics of the patients with stage IV lung cancer harboring uncommon mutation receiving a first-line tyrosine kinase inhibitor (TKI), classified by the drug used.

                                                              Afatinib      Gefitinib     Erlotinib     *p* Value \*
  ----------------------------------------------------------- ------------- ------------- ------------- --------------
  n                                                           17 (30%)      31 (54%)      9 (16%)       
  Age (year), mean ± SD                                       64 ± 9        67 ± 14       62 ± 11       0.4356
  Age (year), median (IQR)                                    65 (61--70)   67 (56--80)   61 (55--67)   0.4356
  Age (year), n (%)                                                                                     0.5820
   \<65                                                       11 (65%)      15 (48%)      5 (56%)       
   ≥65                                                        6 (35%)       16 (52%)      4 (44%)       
  Sex, n (%)                                                                                            0.1084
   Female                                                     8 (47%)       16 (52%)      8 (89%)       0.2477
   Male                                                       9 (53%)       15 (48%)      1 (11%)       
  Smoking history, n (%)                                                                                0.2477
   Never                                                      13 (76%)      19 (61%)      8 (89%)       
   Current                                                    4 (24%)       12 (39%)      1 (11%)       
  Performance status, n (%)                                                                             0.3383
   ECOG 0--1                                                  10 (59%)      21 (68%)      8 (89%)       
   ECOG 2--4                                                  7 (41%)       10 (32%)      1 (11%)       
  Number of metastatic sites, n (%)                                                                     0.3891
   =1                                                         6 (35%)       17 (55%)      4 (44%)       
   ≥2                                                         11 (65%)      14 (45%)      5 (56%)       
  Metastatic site, n (%)                                                                                
   Brain                                                      6 (35%)       5 (16%)       3 (33%)       0.2500
   Leptomeningeal                                             2 (12%)       0 (0%)        0 (0%)        0.1078
   Lung                                                       9 (53%)       8 (26%)       3 (33%)       0.1661
   Bone                                                       8 (47%)       17 (55%)      5 (56%)       0.9344
   Pleural                                                    7 (41%)       19 (61%)      3 (33%)       0.2398
   Pericardial                                                4 (24%)       1 (3%)        0 (0%)        0.0542
   Liver                                                      3 (18%)       5 (16%)       1 (11%)       1.0000
   Adrenal                                                    2 (12%)       2 (6%)        1 (11%)       0.6897
  Mutation site classified by exon, n (%)                                                               0.2374
   Mutation only in exon 18                                   4 (24%)       14 (45%)      3 (33%)       
   Mutation only in exon 20                                   8 (47%)       7 (23%)       1 (11%)       
   Mutation only in exon 21                                   2 (12%)       7 (23%)       4 (44%)       
   Mutations in multiple exons                                3 (18%)       3 (10%)       1 (11%)       
  Mutation site classified by susceptibility †, n (%)                                                   0.1599
   Single sensitizing uncommon mutation                       5 (29%)       16 (52%)      6 (67%)       
   Multiple sensitizing mutations                             3 (18%)       3 (10%)       1 (11%)       
   A sensitizing mutation and a resistant uncommon mutation   0 (0%)        4 (13%)       1 (11%)       
   Other resistant uncommon mutations                         9 (53%)       8 (26%)       1 (11%)       
  Initial response to TKI, n (%)                                                                        0.1943
   Partial response                                           7 (41%)       9 (29%)       3 (33%)       
   Stable disease                                             5 (29%)       11 (35%)      6 (67%)       
   Progressive disease                                        5 (29%)       11 (35%)      0 (0%)        
  Response rate to TKI                                        7 (41%)       9 (29%)       3 (33%)       0.7450
  Disease control rate with TKI                               12 (71%)      20 (65%)      9 (100%)      0.0914
  Median PFS on TKI (month)                                   5.5           6.2           9.0           0.3025
  Median OS (month)                                           20.5          16.1          12.1          0.9116

\* Kruskal-Wallis test or Fisher's exact test or Log-rank test. ^†^ Mutation site classified by susceptibility: "Single sensitizing uncommon mutation" included exon18 G719X and exon21 L861Q; "multiple sensitizing mutations" included exon18 G719X + exon20 S768I, exon18 G719X + exon21 L861Q, and exon21 L858R + exon20 S768I; "a sensitizing mutation and a resistant uncommon mutation" included exon18 G719X + exon18 other and exon21 L858R + exon20 Q812\*; "other resistant uncommon mutations" included exon 18 other mutation, exon 20 insertion, and exon 20 point mutation.
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###### 

Characteristics of the patients with stage IV lung cancer harboring uncommon mutation receiving a first-line tyrosine kinase inhibitor (TKI), classified by the age group.

                                                              Age \< 65     Age ≥ 65      *p* Value \*
  ----------------------------------------------------------- ------------- ------------- --------------
  n                                                           31 (54%)      26 (46%)      
  Age (year), mean ± SD                                       57 ± 7        76 ± 7        \<0.0001
  Age (year), median (IQR)                                    59 (50--62)   77 (71--81)   \<0.0001
  Sex, n (%)                                                                              0.0176
   Female                                                     22 (71%)      10 (38%)      
   Male                                                       9 (29%)       16 (62%)      
  Smoking history, n (%)                                                                  0.2494
   Never                                                      24 (77%)      16 (62%)      
   Current                                                    7 (23%)       10 (38%)      
  Performance status, n (%)                                                               0.0453
   ECOG 0--1                                                  25 (81%)      14 (54%)      
   ECOG 2--4                                                  6 (19%)       12 (46%)      
  Number of metastatic sites, n (%)                                                       0.4311
   =1                                                         13 (42%)      14 (54%)      
   ≥2                                                         18 (58%)      12 (46%)      
  Metastatic site, n (%)                                                                  
   Brain                                                      9 (29%)       5 (19%)       0.5392
   Leptomeningeal                                             1 (3%)        1 (4%)        1.0000
   Lung                                                       11 (35%)      9 (35%)       1.0000
   Bone                                                       17 (55%)      13 (50%)      0.7931
   Pleural                                                    14 (45%)      15 (58%)      0.4287
   Pericardial                                                4 (13%)       1 (4%)        0.3624
   Liver                                                      6 (19%)       3 (12%)       0.4876
   Adrenal                                                    3 (10%)       2 (8%)        1.0000
  Mutation site classified by exon, n (%)                                                 0.7749
   Mutation only in exon 18                                   11 (35%)      10 (38%)      
   Mutation only in exon 20                                   9 (29%)       7 (27%)       
   Mutation only in exon 21                                   6 (19%)       7 (27%)       
   Mutations in multiple exons                                5 (16%)       2 (8%)        
  Mutation site classified by susceptibility ^†^, n (%)                                   0.3426
   Single sensitizing uncommon mutation                       14 (45%)      13 (50%)      
   Multiple sensitizing mutations                             5 (16%)       2 (8%)        
   A sensitizing mutation and a resistant uncommon mutation   1 (3%)        4 (15%)       
   Other resistant uncommon mutations                         11 (35%)      7 (27%)       
  TKI medication, n (%)                                                                   0.5820
   Afatinib                                                   11 (35%)      6 (23%)       
   Gefitinib                                                  15 (48%)      16 (62%)      
   Erlotinib                                                  5 (16%)       4 (15%)       
  Initial response to TKI, n (%)                                                          0.7086
   Partial response                                           9 (29%)       10 (38%)      
   Stable disease                                             12 (39%)      10 (38%)      
   Progressive disease                                        10 (32%)      6 (23%)       
  Response rate to TKI                                        9 (29%)       10 (38%)      0.5748
  Disease control rate with TKI                               21 (68%)      20 (77%)      0.5581
  Median PFS on TKI (month)                                   5.5           10.5          0.0320
  Median OS (month)                                           16.6          16.1          0.8979

\* Kruskal-Wallis test or Fisher's exact test or Log-rank test. ^†^ Mutation site classified by susceptibility: "Single sensitizing uncommon mutation" included exon18 G719X and exon21 L861Q; "multiple sensitizing mutations" included exon18 G719X + exon20 S768I, exon18 G719X + exon21 L861Q, and exon21 L858R + exon20 S768I; "a sensitizing mutation and a resistant uncommon mutation" included exon18 G719X + exon18 other and exon21 L858R + exon20 Q812\*; "other resistant uncommon mutations" included exon 18 other mutation, exon 20 insertion, and exon 20 point mutation.
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###### 

Cox proportional hazards regression analyses for identifying the relationship between clinical features and progression-free survival in patients with stage IV lung cancer harboring uncommon mutation receiving first-line TKI.

                                                              Univariate Analysis   Multivariable Analyses                                               
  ----------------------------------------------------------- --------------------- ------------------------ --------------------- --------------------- ---------------------
  Sex                                                                                                                                                    
   Female                                                     1.00                  1.00                     1.00                  1.00                  1.00
   Male                                                       1.50 \[0.83--2.72\]   2.83 \[1.04--7.72\]      2.90 \[1.07--7.88\]   2.13 \[1.11--4.09\]   2.10 \[1.11--3.97\]
  Age (year)                                                                                                                                             
   \<65                                                       1.00                  1.00                     1.00                  1.00                  1.00
   ≥65                                                        0.52 \[0.28--0.95\]   0.27 \[0.12--0.58\]      0.28 \[0.13--0.60\]   0.35 \[0.17--0.72\]   0.35 \[0.17--0.73\]
  Smoking history                                                                                                                                        
   Never                                                      1.00                  1.00                     1.00                                        
   Current                                                    1.33 \[0.70--2.52\]   0.44 \[0.14--1.42\]      0.46 \[0.15--1.46\]                         
  Performance status                                                                                                                                     
   ECOG 0--1                                                  1.00                  1.00                     1.00                                        
   ECOG 2--4                                                  1.60 \[0.85--3.02\]   1.51 \[0.60--3.84\]      1.52 \[0.62--3.74\]                         
  Number of metastatic sites                                                                                                                             
   =1                                                         1.00                  1.00                     1.00                  1.00                  1.00
   ≥2                                                         1.60 \[0.85--3.02\]   1.65 \[0.78--3.51\]      1.87 \[0.89--3.94\]   1.75 \[0.87--3.54\]   1.73 \[0.84--3.58\]
  Mutation site classified by exon                                                                                                                       
   Mutation only in exon 18                                   1.02 \[0.36--2.84\]   1.31 \[0.42--4.09\]                            1.11 \[0.38--3.20\]   
   Mutation only in exon 20                                   2.25 \[0.78--6.47\]   3.70 \[0.93--14.83\]                           2.84 \[0.94--8.60\]   
   Mutation only in exon 21                                   1.53 \[0.54--4.38\]   1.84 \[0.53--6.43\]                            1.59 \[0.51--5.01\]   
   Mutations in multiple exons                                1.00                  1.00                                           1.00                  
  Mutation site classified by susceptibility ^†^                                                                                                         
   Single sensitizing uncommon mutation                       0.57 \[0.29--1.10\]                            0.39 \[0.16--0.96\]                         0.48 \[0.23--1.02\]
   Multiple sensitizing mutations                             0.43 \[0.15--1.21\]                            0.27 \[0.07--1.01\]                         0.34 \[0.12--1.01\]
   A sensitizing mutation and a resistant uncommon mutation   0.19 \[0.04--0.85\]                            0.20 \[0.04--1.08\]                         0.18 \[0.04--0.83\]
   Other resistant uncommon mutations                         1.00                                           1.00                                        1.00
  TKI medication                                                                                                                                         
   Afatinib                                                   1.00                  1.00                     1.00                                        
   Gefitinib                                                  0.90 \[0.46--1.76\]   1.85 \[0.76--4.46\]      1.90 \[0.82--4.43\]                         
   Erlotinib                                                  0.46 \[0.16--1.30\]   0.91 \[0.27--3.05\]      1.24 \[0.37--4.19\]                         

Model 1 and Model 2 are maximal models. Model 3 and Model 4 are reduced multivariable models developed with backward variable selection method, keeping only variables with *p* value less than 0.15, from Model 1 and Model 2, respectively. ^†^ Mutation site classified by susceptibility: "Single sensitizing uncommon mutation" included exon18 G719X and exon21 L861Q; "multiple sensitizing mutations" included exon18 G719X + exon20 S768I, exon18 G719X + exon21 L861Q, and exon21 L858R + exon20 S768I; "a sensitizing mutation and a resistant uncommon mutation" included exon18 G719X + exon18 other and exon21 L858R + exon20 Q812\*; "other resistant uncommon mutations" included exon 18 other mutation, exon 20 insertion, and exon 20 point mutation.
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###### 

Cox proportional hazards regression analyses for identifying the relationship between clinical features and overall survival in patients with stage IV lung cancer harboring uncommon mutation receiving first-line TKI.

                                                              Univariate Analysis   Multivariable Analyses                         
  ----------------------------------------------------------- --------------------- ------------------------ --------------------- ---------------------
  Sex                                                                                                                              
   Female                                                     1.00                  1.00                     1.00                  1.00
   Male                                                       2.31 \[1.19--4.47\]   1.81 \[0.65--4.98\]      1.86 \[0.67--5.16\]   1.83 \[0.88--3.78\]
  Age (year)                                                                                                                       
   \<65                                                       1.00                  1.00                     1.00                  1.00
   ≥65                                                        1.04 \[0.55--1.98\]   0.45 \[0.18--1.12\]      0.46 \[0.19--1.15\]   0.47 \[0.20--1.14\]
  Smoking history                                                                                                                  
   Never                                                      1.00                  1.00                     1.00                  
   Current                                                    2.40 \[1.21--4.74\]   1.11 \[0.37--3.3\]       1.1 \[0.36--3.33\]    
  Performance status                                                                                                               
   ECOG 0--1                                                  1.00                  1.00                     1.00                  1.00
   ECOG 2--4                                                  2.77 \[1.42--5.39\]   3.43 \[1.21--9.75\]      3.32 \[1.19--9.28\]   3.40 \[1.32--8.72\]
  Number of metastatic sites                                                                                                       
   =1                                                         1.00                  1.00                     1.00                  
   ≥2                                                         2.77 \[1.42--5.39\]   1.10 \[0.49--2.46\]      1.20 \[0.55--2.60\]   
  Mutation site classified by exon                                                                                                 
   Mutation only in exon 18                                   1.39 \[0.45--4.30\]   1.56 \[0.43--5.62\]                            
   Mutation only in exon 20                                   1.73 \[0.55--5.48\]   1.26 \[0.34--4.73\]                            
   Mutation only in exon 21                                   1.95 \[0.61--6.24\]   1.90 \[0.43--8.48\]                            
   Mutations in multiple exons                                1.00                  1.00                                           
  Mutation site classified by susceptibility                                                                                       
   Single sensitizing uncommon mutation                       0.86 \[0.41--1.78\]                            1.15 \[0.49--2.7\]    
   Multiple sensitizing mutations                             0.56 \[0.18--1.74\]                            0.75 \[0.21--2.67\]   
   A sensitizing mutation and a resistant uncommon mutation   1.01 \[0.33--3.12\]                            1.23 \[0.34--4.44\]   
   Other resistant uncommon mutations                         1.00                                           1.00                  
  TKI medication                                                                                                                   
   Afatinib                                                   1.00                  1.00                     1.00                  
   Gefitinib                                                  1.04 \[0.48--2.24\]   0.85 \[0.33--2.21\]      0.91 \[0.35--2.36\]   
   Erlotinib                                                  0.83 \[0.25--2.71\]   0.93 \[0.22--3.95\]      1.01 \[0.22--4.49\]   

\* Model 1 and Model 2 are maximal models. Model 3 is a reduced multivariable models developed with backward variable selection method, keeping only variables with *p* value less than 0.15, from both Model 1 and Model 2. ^†^ Mutation site classified by susceptibility: "Single sensitizing uncommon mutation" included exon18 G719X and exon21 L861Q; "multiple sensitizing mutations" included exon18 G719X + exon20 S768I, exon18 G719X + exon21 L861Q, and exon21 L858R + exon20 S768I; "a sensitizing mutation and a resistant uncommon mutation" included exon18 G719X + exon18 other and exon21 L858R + exon20 Q812\*; "other resistant uncommon mutations" included exon 18 other mutation, exon 20 insertion, and exon 20 point mutation.
